New research from a phase 2b trial presented at American College of Cardiology meeting (ACC) 2023 suggests an oral PCSK9 inhibitor could help reduce LDL-C by 60% in patients with or at-risk for atherosclerotic cardiovascular disease.

“This is a highly effective compound that was well tolerated,” said lead investigator Christie M. Ballantyne, MD, director of the Center for Metabolic Disease Prevention at Baylor College of Medicine.

“MK-0616 could offer another potential option. Between this and statins and the other therapies we have, we should be able to basically treat almost everybody in terms of LDL cholesterol.”

One of the most significant advances in lipid management in the 21st century, PCSK9 inhibitors ushered in a new era of LDL-C lowering. However, as with all injectable agents, some patients opt against use despite the proven efficacy of agents within the class.

Read More